These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 38244704)

  • 1. Intrahepatic cholangiocarcinoma biomarkers: Towards early detection and personalized pharmacological treatments.
    Capuozzo M; Santorsola M; Ferrara F; Cinque C; Farace S; Patrone R; Granata V; Zovi A; Nasti G; Ottaiano A
    Mol Cell Probes; 2024 Feb; 73():101951. PubMed ID: 38244704
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Is nestin a diagnostic marker for combined hepatocellular-cholangiocarcinoma?
    Sasaki M; Sato Y; Nakanuma Y
    Histopathology; 2022 Apr; 80(5):859-868. PubMed ID: 35076959
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intrahepatic cholangiocarcinoma: Tumour heterogeneity and its clinical relevance.
    Komuta M
    Clin Mol Hepatol; 2022 Jul; 28(3):396-407. PubMed ID: 35032970
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Revealing the role of necroptosis microenvironment: FCGBP + tumor-associated macrophages drive primary liver cancer differentiation towards cHCC-CCA or iCCA.
    Wang C; Chen C; Hu W; Tao L; Chen J
    Apoptosis; 2024 Apr; 29(3-4):460-481. PubMed ID: 38017206
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biomarkers of intrahepatic cholangiocarcinoma: diagnosis and response to therapy.
    Brown ZJ; Hewitt DB; Pawlik TM
    Front Biosci (Landmark Ed); 2022 Mar; 27(3):85. PubMed ID: 35345317
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An Expert, Multidisciplinary Perspective on Best Practices in Biomarker Testing in Intrahepatic Cholangiocarcinoma.
    Madoff DC; Abi-Jaoudeh N; Braxton D; Goyal L; Jain D; Odisio BC; Salem R; Schattner M; Sheth R; Li D
    Oncologist; 2022 Oct; 27(10):884-891. PubMed ID: 35925597
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of Clinical Features and Outcomes Between Intrahepatic Cholangiocarcinoma and Hepatocellular Carcinoma in the United States.
    Lee YT; Wang JJ; Luu M; Noureddin M; Nissen NN; Patel TC; Roberts LR; Singal AG; Gores GJ; Yang JD
    Hepatology; 2021 Nov; 74(5):2622-2632. PubMed ID: 34114675
    [TBL] [Abstract][Full Text] [Related]  

  • 8. EASL-ILCA Clinical Practice Guidelines on the management of intrahepatic cholangiocarcinoma.
    European Association for the Study of the Liver
    J Hepatol; 2023 Jul; 79(1):181-208. PubMed ID: 37084797
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Subcentimetric Incidental Intrahepatic Cholangiocarcinoma in an Explant Liver: Diagnostic Difficulty of a Rare Entity.
    Mitra S; Geethanjali G; Rathi S; Behera A; Das A
    Int J Surg Pathol; 2018 Dec; 26(8):739-744. PubMed ID: 29742944
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Liquid biopsy-based protein biomarkers for risk prediction, early diagnosis, and prognostication of cholangiocarcinoma.
    Lapitz A; Azkargorta M; Milkiewicz P; Olaizola P; Zhuravleva E; Grimsrud MM; Schramm C; Arbelaiz A; O'Rourke CJ; La Casta A; Milkiewicz M; Pastor T; Vesterhus M; Jimenez-Agüero R; Dill MT; Lamarca A; Valle JW; Macias RIR; Izquierdo-Sanchez L; Pérez Castaño Y; Caballero-Camino FJ; Riaño I; Krawczyk M; Ibarra C; Bustamante J; Nova-Camacho LM; Falcon-Perez JM; Elortza F; Perugorria MJ; Andersen JB; Bujanda L; Karlsen TH; Folseraas T; Rodrigues PM; Banales JM
    J Hepatol; 2023 Jul; 79(1):93-108. PubMed ID: 36868481
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treating Hepatobiliary Cancers: The Oncology Way.
    Galle PR
    Dig Dis; 2017; 35(4):384-386. PubMed ID: 28468016
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pathological aspects of mucinous cholangiocarcinoma: A single-center experience and systematic review.
    Laohawetwanit T; Klaikaew N
    Pathol Int; 2020 Sep; 70(9):661-670. PubMed ID: 32638458
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of N-linked Glycan Alterations in Tissue and Serum Reveals Promising Biomarkers for Intrahepatic Cholangiocarcinoma.
    Ochoa-Rios S; Blaschke CRK; Wang M; Peterson KD; DelaCourt A; Grauzam SE; Lewin D; Angel P; Roberts LR; Drake R; Mehta AS
    Cancer Res Commun; 2023 Mar; 3(3):383-394. PubMed ID: 36890858
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HNF-1β is a More Sensitive and Specific Marker Than C-Reactive Protein for Identifying Biliary Differentiation in Primary Hepatic Carcinomas.
    Patil PA; Taddei T; Jain D; Zhang X
    Arch Pathol Lab Med; 2022 Jan; 146(2):220-226. PubMed ID: 34086854
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biomarkers for Hepatobiliary Cancers.
    Nault JC; Villanueva A
    Hepatology; 2021 Jan; 73 Suppl 1():115-127. PubMed ID: 32045030
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum CYFRA 21-1 in Biliary Tract Cancers: A Reliable Biomarker for Gallbladder Carcinoma and Intrahepatic Cholangiocarcinoma.
    Huang L; Chen W; Liang P; Hu W; Zhang K; Shen S; Chen J; Zhang Z; Chen B; Han Y; Meng F; DeMorrow S; Yin X; Lai J; Liang L
    Dig Dis Sci; 2015 May; 60(5):1273-83. PubMed ID: 25487191
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunotherapies for hepatocellular carcinoma and intrahepatic cholangiocarcinoma: Current and developing strategies.
    Argemi J; Ponz-Sarvise M; Sangro B
    Adv Cancer Res; 2022; 156():367-413. PubMed ID: 35961706
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Keratin 19-expressing hepatocellular carcinoma and small-duct type intrahepatic cholangiocarcinoma show a similar postoperative clinical course but have distinct genetic features.
    Akita M; Ajiki T; Fukumoto T; Itoh T; Zen Y
    Histopathology; 2019 Sep; 75(3):385-393. PubMed ID: 31017316
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intrahepatic cholangiocarcinoma with increased serum CYFRA 21-1 level.
    Kashihara T; Ohki A; Kobayashi T; Sato T; Nishizawa H; Ogawa K; Tako H; Kawakami F; Tsuji M; Tamaoka K
    J Gastroenterol; 1998 Jun; 33(3):447-53. PubMed ID: 9658330
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bile duct adenoma may be a precursor lesion of small duct type intrahepatic cholangiocarcinoma.
    Sasaki M; Sato Y; Nakanuma Y
    Histopathology; 2021 Jan; 78(2):310-320. PubMed ID: 33405289
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.